CA3143790A1 - Therapeutic interactions of leucomethylthioninium - Google Patents

Therapeutic interactions of leucomethylthioninium Download PDF

Info

Publication number
CA3143790A1
CA3143790A1 CA3143790A CA3143790A CA3143790A1 CA 3143790 A1 CA3143790 A1 CA 3143790A1 CA 3143790 A CA3143790 A CA 3143790A CA 3143790 A CA3143790 A CA 3143790A CA 3143790 A1 CA3143790 A1 CA 3143790A1
Authority
CA
Canada
Prior art keywords
treatment
compound
therapeutic
subject
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3143790A
Other languages
English (en)
French (fr)
Inventor
Charles Robert Harrington
Gernot Riedel
Valeria MELIS
Jochen Klein
Grazyna NIEWIADOMSKA
Marta STECZKOWSKA
Karima SCHWAB
Claude Michel Wischik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wista Laboratories Ltd
Original Assignee
Wista Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wista Laboratories Ltd filed Critical Wista Laboratories Ltd
Publication of CA3143790A1 publication Critical patent/CA3143790A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Steroid Compounds (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
CA3143790A 2019-07-01 2020-06-30 Therapeutic interactions of leucomethylthioninium Pending CA3143790A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1909493.7 2019-07-01
GBGB1909493.7A GB201909493D0 (en) 2019-07-01 2019-07-01 Therapeutic interactions
PCT/EP2020/068422 WO2021001380A1 (en) 2019-07-01 2020-06-30 Therapeutic interactions of leucomethylthioninium

Publications (1)

Publication Number Publication Date
CA3143790A1 true CA3143790A1 (en) 2021-01-07

Family

ID=67540109

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3143790A Pending CA3143790A1 (en) 2019-07-01 2020-06-30 Therapeutic interactions of leucomethylthioninium

Country Status (12)

Country Link
US (1) US20230031369A1 (enExample)
EP (1) EP3989954A1 (enExample)
JP (1) JP7638915B2 (enExample)
KR (1) KR20220027203A (enExample)
CN (1) CN114126622A (enExample)
AU (1) AU2020298758B2 (enExample)
BR (1) BR112021025256A2 (enExample)
CA (1) CA3143790A1 (enExample)
GB (1) GB201909493D0 (enExample)
IL (1) IL289338B2 (enExample)
MX (1) MX2021015292A (enExample)
WO (1) WO2021001380A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3487505T3 (pl) 2016-07-25 2023-10-09 Wista Laboratories Ltd. Podawanie i dawkowanie diaminofenotiazyn
BR112021000802A2 (pt) 2018-07-26 2021-04-13 Wista Laboratories Ltd. Dosagem otimizada de diaminofenotiazinas em populações
GB202500018D0 (en) * 2025-01-02 2025-02-19 Wista Lab Ltd Long term dosing of neurodegenerative disorders utilising methylthioninium (mt) containing compounds

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0100119D0 (en) 2001-01-03 2001-02-14 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
GB0106953D0 (en) 2001-03-20 2001-05-09 Univ Aberdeen Neufofibrillary labels
CN104119294B (zh) 2006-03-29 2018-10-30 维斯塔实验室有限公司 3,7-二氨基-10h-吩噻嗪化合物的制备方法
AU2008265045B2 (en) 2007-06-19 2014-02-27 Taurx Therapeutics Management Ltd. Phenothiazine compounds for treating Mild Cognitive Impairment
PT2954932T (pt) 2007-10-03 2018-12-12 Wista Lab Ltd Utilização terapêutica de diaminofenotiazinas
CN101911081A (zh) 2007-11-05 2010-12-08 维斯塔实验室有限公司 用于临床试验的体系
KR101888713B1 (ko) 2011-02-11 2018-08-14 위스타 레보레이토리스 리미티드 페노티아진 디아미늄 염 및 이의 용도
PL3487505T3 (pl) 2016-07-25 2023-10-09 Wista Laboratories Ltd. Podawanie i dawkowanie diaminofenotiazyn
GB201614834D0 (en) * 2016-09-01 2016-10-19 Wista Lab Ltd Treatment of dementia
BR112021000802A2 (pt) * 2018-07-26 2021-04-13 Wista Laboratories Ltd. Dosagem otimizada de diaminofenotiazinas em populações

Also Published As

Publication number Publication date
WO2021001380A1 (en) 2021-01-07
US20230031369A1 (en) 2023-02-02
GB201909493D0 (en) 2019-08-14
IL289338B2 (en) 2026-07-01
AU2020298758A1 (en) 2022-02-24
IL289338B1 (en) 2026-03-01
EP3989954A1 (en) 2022-05-04
JP7638915B2 (ja) 2025-03-04
IL289338A (en) 2022-02-01
JP2022538642A (ja) 2022-09-05
BR112021025256A2 (pt) 2022-01-25
MX2021015292A (es) 2022-01-18
AU2020298758B2 (en) 2026-07-30
KR20220027203A (ko) 2022-03-07
CN114126622A (zh) 2022-03-01

Similar Documents

Publication Publication Date Title
DK2954932T3 (en) THERAPEUTIC USE OF DIAMINOPHENOTHIAZINES
KR102559354B1 (ko) 치매 치료
JP7686581B2 (ja) 認知機能の向上薬としてのメチルチオニニウム
JP2017137298A (ja) ラキニモドおよびフィンゴリモドを組み合わせた多発性硬化症の治療
US20200113882A1 (en) Use of 4-Aminopyridine to Improve Neuro-Cognitive and/or Neuro-Psychiatric Impairment in Patients with Demyelinating and Other Nervous System Conditions
US20230031369A1 (en) Therapeutic interactions of leucomethylthioninium
US20220370470A1 (en) Methylthioninium for use in the treatment of synaptopathies
RU2834773C2 (ru) Терапевтические взаимодействия лейкометилтиониния
RU2824584C2 (ru) Метилтиониний в качестве усилителя когнитивной функции
Ligsay et al. Overview of targeted double-blind, placebo-controlled clinical trials in fragile X syndrome
KR20160085757A (ko) 다발성 경화증의 치료를 위한 라퀴니모드 병용 치료
EP4340834A1 (en) Method of treating alzheimer's disease
HK1211889B (en) Therapeutic use of diaminophenothiazines
JP2017501230A (ja) ラキニモドおよびテリフルノミドの組合せを用いた多発性硬化症の治療

Legal Events

Date Code Title Description
D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20240826

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20240826

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241007

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241017

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250310

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250331

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250430

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250509

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250509

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250512

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250925

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20260126

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260424

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260424

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260713